Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (61-70 of 325) with videos related to

Pageof 33
Sort By:
Blood|April 28, 2007
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cellsAndrei V Ougolkov, Nancy D Bone, Martin E Fernandez-Zapico, et al.
British Journal of Haematology|September 25, 2014
Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cellsMotofumi Kumazoe, Shuntaro Tsukamoto, Connie Lesnick, et al.
British Journal of Haematology|May 26, 2016
SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cellsShuntaro Tsukamoto, Motofumi Kumazoe, Yuhui Huang, et al.
Blood|December 19, 2009
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progressionAsish K Ghosh, Charla R Secreto, Traci R Knox, et al.
Plos One|October 15, 2011
Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expressionAlbert Gutierrez, Bonnie K Arendt, Renee C Tschumper, et al.
Leukemia Research|February 27, 2009
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology GroupMartha Q Lacy, Susanna Jacobus, Emily A Blood, et al.
Blood|December 8, 2010
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapyAsish K Ghosh, Charla Secreto, Justin Boysen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemiaTait D Shanafelt, Diane Jelinek, Renee Tschumper, et al.
Leukemia Research|January 24, 2007
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch"Neil E Kay, Tait D Shanafelt, Ann K Strege, et al.
Leukemia|March 21, 2026
Defining the acute BTK-loss transcriptional program in CLL using a BTK degraderMingma G Sherpa, Sutapa Sinha, Weiguo Han, et al.
Pageof 33

Showing results (61-70 of 325) with videos related to

Sort By:
Pageof 33
Blood|April 28, 2007
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cellsAndrei V Ougolkov, Nancy D Bone, Martin E Fernandez-Zapico, et al.
British Journal of Haematology|September 25, 2014
Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cellsMotofumi Kumazoe, Shuntaro Tsukamoto, Connie Lesnick, et al.
British Journal of Haematology|May 26, 2016
SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cellsShuntaro Tsukamoto, Motofumi Kumazoe, Yuhui Huang, et al.
Blood|December 19, 2009
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progressionAsish K Ghosh, Charla R Secreto, Traci R Knox, et al.
Plos One|October 15, 2011
Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expressionAlbert Gutierrez, Bonnie K Arendt, Renee C Tschumper, et al.
Leukemia Research|February 27, 2009
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology GroupMartha Q Lacy, Susanna Jacobus, Emily A Blood, et al.
Blood|December 8, 2010
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapyAsish K Ghosh, Charla Secreto, Justin Boysen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemiaTait D Shanafelt, Diane Jelinek, Renee Tschumper, et al.
Leukemia Research|January 24, 2007
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch"Neil E Kay, Tait D Shanafelt, Ann K Strege, et al.
Leukemia|March 21, 2026
Defining the acute BTK-loss transcriptional program in CLL using a BTK degraderMingma G Sherpa, Sutapa Sinha, Weiguo Han, et al.
Pageof 33